Showing results (101-110 of 185) with videos related to
Sort By:
Pageof 19
Scientific Reports|May 19, 2022
C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinibToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 20, 2021
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysisAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Cancer Medicine|April 20, 2022
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.European Journal of Gastroenterology & Hepatology|February 16, 2022
Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Cancer Medicine|December 9, 2022
New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation studyToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Cancer Medicine|September 26, 2022
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysisTakeshi Hatanaka, Atsushi Naganuma, Atsushi Hiraoka, et al.Journal of Viral Hepatitis|July 7, 2019
Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in JapanHiroki Ikeda, Tsunamasa Watanabe, Masanori Atsukawa, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 26, 2022
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysisTakeshi Hatanaka, Atsushi Hiraoka, Toshifumi Tada, et al.BMC Gastroenterology|April 2, 2023
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practiceSae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, et al.Cancer Medicine|December 15, 2022
Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Pageof 19